Annexon’s GA drug misses on primary goal but win on visual acuity will be focus of planned late-stage trial

Kyle LaHucik

Senior Reporter

Annexon’s complement inhibitor didn’t prove better than sham at reducing lesion growth in a leading cause of blindness, but the biotech still plans to move …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Annexon’s GA drug misses on primary goal but win on visual acuity will be focus of planned late-stage trial

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Boehringer’s updated results in HER2-mutated lung cancer impress

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

An­nex­on’s GA drug miss­es on pri­ma­ry goal but win on vi­su­al acu­ity will be fo­cus of planned late-stage tri­al

Senior Reporter

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Annexon’s GA drug misses on primary goal but win on visual acuity will be focus of planned late-stage trial